Methylglyoxal Modified Proteins antibody

Catalog No. ABIN1108230

The Mouse Monoclonal anti-Methylglyoxal Modified Proteins antibody (Clone MGO-1) (ABIN1108230) specifically detects Methylglyoxal Modified Proteins in IHC (p), WB and EIA. The antibody is reactive with Various Species samples.

Quick Overview for Methylglyoxal Modified Proteins antibody (ABIN1108230)

Target: Methylglyoxal Modified Proteins

Reactivity: Various Species

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB), Enzyme Immunoassay (EIA)

Clone: MGO-1

Product Details

Cross-Reactivity (Details): Species reactivity (tested):Human. Multispecies cross reactant.

Purification: Protein G

Immunogen: MGO-modified KLH

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.1 mg/mL

Buffer: PBS, 0.02 % sodium azide, 0.1 % bovine serum albumin

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store at 2 - 8 °C.

Target Details

Target: Methylglyoxal Modified Proteins

Background: Methylglyoxal (MGO) is an endogenous product of glucose metabolism. Increased production and accumulation of methylglyoxal (MGO), as well as increased modification of proteins by glycoxidation, are hallmarks of aging and diabetes. MGO was shown to modify proteins and to contribute to the accumulation of damaged proteins that can be toxic to cells. A number of studies have shown that MGO levels are significantly elevated in patients with Type 2 Diabetes and correlates well with fasting plasma glucose and hemoglobin A1c (HbA1c) levels. Moreover, increased formation of the MGO is implicated in renal dysfunction and is known to be involved in the development of DN (diabetic nephropathy).